SciBX: Science-Business eXchange Contents: July 21 2011, Volume 4 / Issue 28

TABLE OF CONTENTS July 21 2011, Volume 4 / Issue 28 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine disease Gastrointestinal disease Hematology Infectious disease Musculoskeletal disease Neurology Other Various The Distillery: Techniques Assays and screens Drug platforms Markers Recommend to your library Web feed Available online only Subscribe Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Crossing over to bispecificity Chris Cain doi:10.1038/scibx.2011.783 Roche has developed a way to produce bispecific antibodies derived from existing mAbs. By preserving structural similarity to IgG, the approach could minimize immunogenicity and provide pharmacokinetics on par with natural antibodies while maintaining the ability to inhibit two targets at once. Full Text | PDF Targets and Mechanisms Top Celgene skips SKP2 Joanne Kotz doi:10.1038/scibx.2011.784 The biotech and its academic collaborators designed what looked to be a promising small molecule inhibitor of the SKP2 ubiquitin ligase complex. But the company concluded it would be difficult to optimize the cancer compound and now is setting its sights on undisclosed targets outside the ubiquitin pathway. Full Text | PDF Tools Top Repairing the heart from within Kai-Jye Lou doi:10.1038/scibx.2011.785 U.K. researchers have shown that priming epicardial progenitor cells with RegeneRx's thymosin β4 peptide could promote the generation of mature cardiomyocytes after myocardial infarction. The findings point to an alternative to cell transplants to help decrease ischemic injury and increase cardiac repair after a heart attack. Full Text | PDF Marked for ESRD Lauren Martz doi:10.1038/scibx.2011.786 University of Miami researchers have found that FGF23 could help predict whether a patient with early stages of kidney disease is at risk of progressing to and dying from ESRD. However, other researchers are not yet convinced the biomarker will alter treatment decisions. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Tumor necrosis factor receptor superfamily member 21 (TNFRSF21; DR6) doi:10.1038/scibx.2011.787 In vitro and rodent studies suggest antagonizing DR6 could help treat MS. Full Text | PDF Cancer Top Cell division cycle 34 homolog (CDC34); S-phase kinase–associated protein 2 (SKP2) doi:10.1038/scibx.2011.788 An in vitro study suggests inhibiting CDC34 could help treat cancer. Full Text | PDF Lactadherin (MFGE8; HMFG) doi:10.1038/scibx.2011.789 Mouse studies suggest inhibiting MFGE8 could help decrease chemotherapy resistance. Full Text | PDF CD160; CD23; CD5 doi:10.1038/scibx.2011.790 Human studies suggest CD160 expression could help diagnose CLL. Full Text | PDF DEP domain containing 5 (DEPDC5) doi:10.1038/scibx.2011.791 Genomewide association studies identified a SNP in the DEPDC5 gene that could help predict risk of HCV-related hepatocellular carcinoma (HCC). Full Text | PDF Androgen receptor; FK506 binding protein 4 (FKBP4); prostate-specific antigen (KLK3; PSA) doi:10.1038/scibx.2011.792 Cell culture studies identified compounds that block FKBP4–androgen receptor interactions and could help treat prostate cancer. Full Text | PDF Cardiovascular disease Top Store overload–induced Ca2+ release (SOICR) doi:10.1038/scibx.2011.793 In vitro and mouse studies suggest SOICR inhibitors could increase the efficacy of β-blockers to prevent ventricular arrhythmia. Full Text | PDF Endocrine disease Top Insulin doi:10.1038/scibx.2011.794 Studies in mice suggest vaccination with a modified insulin epitope could help prevent type 1 diabetes. Full Text | PDF Cannabinoid CB1 receptor (CNR1) doi:10.1038/scibx.2011.795 Rat studies suggest inhibiting CNR1 in the intestine could help treat obesity. Full Text | PDF Gastrointestinal disease Top Not applicable doi:10.1038/scibx.2011.796 Mouse studies suggest retinoic acid could boost the efficacy of vaccines to prevent enteric bacterial infection and infectious diarrhea. Full Text | PDF Hematology Top Hemochromatosis type 2 juvenile (HFE2); hepcidin doi:10.1038/scibx.2011.797 A study in rats suggests a soluble form of HFE2 may help treat anemia of chronic disease. Full Text | PDF Infectious disease Top Influenza virus hemagglutinin 2 (HA2) doi:10.1038/scibx.2011.798 In vitro and mouse studies suggest targeting a broadly neutralizing influenza epitope could help prevent or treat H3N2, H7N7 and other influenza A group 2 infections. Full Text | PDF Not applicable doi:10.1038/scibx.2011.799 Mouse studies suggest bisphosphonates could help treat influenza A infection. Full Text | PDF Musculoskeletal disease Top RNA doi:10.1038/scibx.2011.800 Fruit fly and mouse studies identified a d-amino-acid hexapeptide that could help treat muscular dystrophy. Full Text | PDF Neurology Top Chemokine CXC motif ligand 5 (CXCL5; ENA78) doi:10.1038/scibx.2011.801 A study in humans and in rats suggests antagonizing CXCL5 could treat sunburn-associated pain. Full Text | PDF Chemokine CX3C motif receptor 1 (CX3CR1) doi:10.1038/scibx.2011.802 Mouse studies suggest inhibiting CX3CR1 could help treat SCI. Full Text | PDF Perlecan doi:10.1038/scibx.2011.803 Rodent studies suggest that perlecan domain V (DV) could help treat stroke. Full Text | PDF Other Top Mammalian target of rapamycin (mTOR; FRAP; RAFT1) doi:10.1038/scibx.2011.804 Cell culture studies suggest rapamycin or another mTOR inhibitor could help treat Hutchinson-Gilford progeria syndrome (HGPS), which causes premature aging and can lead to death from cardiovascular complications. Full Text | PDF Various Top Protein phosphatase methylesterase 1 (PPME1); protein phosphatase 2 (PPP2CA; PP2A) doi:10.1038/scibx.2011.805 An in vitro study identified sulfonyl acrylonitrile–based inhibitors of PPME1 that could help treat cancer and AD. Full Text | PDF Nuclear receptor subfamily 0 group B member 2 (NR0B2; SHP) doi:10.1038/scibx.2011.806 Mouse and cell culture studies suggest increasing SHP activity could help treat sepsis and inflammation. Full Text | PDF CD5 molecule-like (CD5L; AIM) doi:10.1038/scibx.2011.807 Studies in mice suggest antagonizing CD5L could help prevent progression from obesity to metabolic syndrome and type 2 diabetes. Full Text | PDF Distillery: Techniques Assays and screens Top Mice with human ectopic artificial livers (HEALs) to predict human drug metabolism and drug-drug interactions doi:10.1038/scibx.2011.808 Mice with HEALs could be used to predict human drug metabolism and drug-drug interactions. Full Text | PDF Drug platforms Top Vaccine targeting heroin and its psychoactive metabolites doi:10.1038/scibx.2011.809 A vaccine that targets heroin and its psychoactive metabolites could help improve heroin rehabilitation therapy. Full Text | PDF Markers Top Gene signature to predict vaccine immunogenicity doi:10.1038/scibx.2011.810 Gene expression studies show that distinct gene signatures generated after vaccination could help predict vaccine immunogenicity. Full Text | PDF VEGF receptor 1 (FLT1) expression as a marker for predicting response to anti–placental growth factor (PGF; PlGF) therapies doi:10.1038/scibx.2011.811 FLT1 expression could help predict whether cancer patients will respond to anti-PlGF therapies. Full Text | PDF

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.